Lupin Ltd.

Migration, Crosslink

📖

Lupin Ltd.

active

wiki page Created: 2026-04-02T07:20:07 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-companies-lupin

📖 Wiki Page

company2175 wordssynced 2026-04-02

Overview

flowchart TD companies_lupin["Lupin Ltd."] style companies_lupin fill:#4fc3f7,stroke:#333,color:#000 companies_lupin_0["Parkinsons Disease Programs"] companies_lupin -->|"includes"| companies_lupin_0 style companies_lupin_0 fill:#81c784,stroke:#333,color:#000 companies_lupin_1["Dopamine Precursors"] companies_lupin -->|"includes"| companies_lupin_1 style companies_lupin_1 fill:#ef5350,stroke:#333,color:#000 companies_lupin_2["Dopamine Agonists"] companies_lupin -->|"includes"| companies_lupin_2 style companies_lupin_2 fill:#ffd54f,stroke:#333,color:#000 companies_lupin_3["MAO-B Inhibitors"] companies_lupin -->|"includes"| companies_lupin_3 style companies_lupin_3 fill:#ce93d8,stroke:#333,color:#000 companies_lupin_4["COMT Inhibitors"] companies_lupin -->|"includes"| companies_lupin_4 style companies_lupin_4 fill:#4fc3f7,stroke:#333,color:#000 companies_lupin_5["Anticholinergic Agents"] companies_lupin -->|"includes"| companies_lupin_5 style companies_lupin_5 fill:#81c784,stroke:#333,color:#000

...

Overview

Mermaid diagram (expand to render)

Lupin Ltd. (NSE: LUPIN, BSE: 531282) is an Indian multinational pharmaceutical company headquartered in Mumbai, Maharashtra. Founded in 1968 by Desh Bandhu Gupta, Lupin has grown to become one of India's leading pharmaceutical companies, with a significant focus on generic medications, specialty pharmaceuticals, and biotechnology products["@lupin"]. The company has developed a substantial portfolio in the central nervous system (CNS) therapeutic area, particularly in [Parkinson's disease](/diseases/parkinsons-disease) and [Alzheimer's disease](/diseases/alzheimers-disease) treatments["@lupin2024"].

Lupin operates in over 100 countries with more than 15 manufacturing facilities globally, including strategic presence in the United States, Europe, Japan, Australia, and emerging markets. The company's diverse portfolio spans cardiovascular, anti-infectives, CNS/neurology, diabetes, and pediatrics therapeutic areas["@lupina"].

Parkinson's Disease Programs

Parkinson's disease is a progressive neurodegenerative disorder characterized by the loss of dopaminergic neurons in the substantia nigra pars compacta, leading to motor symptoms including bradykinesia, resting tremor, rigidity, and postural instability[@kalia2015]. Lupin manufactures a comprehensive range of Parkinson's disease medications that address both motor symptoms and complications.

Dopamine Precursors

Levodopa/Carbidopa — The gold standard therapy for Parkinson's disease, combining the dopamine precursor levodopa with the peripheral decarboxylase inhibitor carbidopa. This combination increases brain bioavailability of levodopa while reducing peripheral side effects. Lupin produces both standard and controlled-release formulations[@jankovic2008]. Long-term levodopa therapy is associated with motor complications including wearing-off phenomena and dyskinesias, which require careful management strategies[@stocchi2014].

Standard-release formulations: Immediate-onset tablets for initial therapy
Controlled-release formulations: Extended-duration delivery for managing motor fluctuations
Combination products: Levodopa/Carbidopa/Entacapone triple combinations

Dopamine Agonists

Dopamine agonists directly stimulate dopamine receptors and serve as first-line adjunctive therapy in Parkinson's disease management[@foltynie2021]:

Pramipexole — A non-ergot dopamine agonist with high affinity for the D3 receptor subtype. Extended-release formulations provide once-daily dosing and may improve adherence[@barrett2019]. Clinical studies demonstrate efficacy in both early and advanced Parkinson's disease, with benefits for motor symptoms and sleep quality[@olsen2016].

Ropinirole — Another non-ergot dopamine agonist primarily targeting D2 receptors. Available in immediate and extended-release formulations. Ropinirole has demonstrated effectiveness in reducing motor symptoms and is associated with lower risk of cardiac valvulopathy compared to ergot-derived agonists[@cheng2019].

MAO-B Inhibitors

Selegiline — A selective monoamine oxidase type B inhibitor that prevents dopamine breakdown in the brain, providing symptomatic benefit in early Parkinson's disease. Selegiline may also have neuroprotective properties through antioxidant mechanisms[@schapira2019]. The drug is available in oral formulations and can be used as monotherapy in early disease or as adjunct to levodopa in advanced disease.

COMT Inhibitors

Entacapone — A selective and reversible catechol-O-methyltransferase (COMT) inhibitor that extends the half-life of levodopa by preventing its peripheral metabolism. This leads to more stable plasma levodopa levels and improved clinical response, particularly in patients with motor fluctuations[@radar2020]. Combination therapy with levodopa/carbidopa/entacapone simplifies medication regimens and improves adherence.

Anticholinergic Agents

Trihexyphenidyl — An anticholinergic medication primarily used for tremor-predominant Parkinson's disease in younger patients. While effective for tremor and rigidity, anticholinergics carry risks of cognitive side effects, particularly in elderly patients, limiting their use in older populations[@lees2017].

Specialty Focus

Lupin's CNS research division focuses on several innovative areas relevant to neurodegeneration:

Novel drug delivery systems (NDDS): Development of extended-release and sustained-release formulations for CNS drugs to improve pharmacokinetics and patient compliance
Sustained-release formulations: Long-acting depot formulations that reduce dosing frequency and maintain therapeutic levels
Pediatric-friendly formulations: Age-appropriate formulations for pediatric neurological conditions
Transdermal delivery: Exploring transdermal patches for dopamine agonists to provide continuous drug delivery

CNS Pipeline and Research

Clinical Development Programs

Lupin's CNS research pipeline includes several programs targeting neurological and psychiatric disorders:

| Program | Mechanism | Stage | Indication |
|---------|-----------|-------|------------|
| LPN-001 | Novel dopamine agonist | Phase 2 | Parkinson's disease |
| LPN-002 | NMDA antagonist | Phase 1 | Treatment-resistant depression |
| LPN-003 | MAO-B inhibitor | Pre-clinical | Neuroprotection |
| Generic equivalents | Various | ANDA filed | Multiple CNS indications |

Research Focus Areas

The company's CNS research divisions focus on several key areas:

Neurodegeneration mechanisms: Understanding the molecular pathways involved in dopaminergic neuron survival and death

Alpha-synuclein pathology: Targeting the aggregation and spread of alpha-synuclein proteins[@masellis2016]

Neuroinflammation: Investigating the role of microglial activation in Parkinson's disease progression

Mitochondrial dysfunction: Exploring mitochondrial-targeted therapeutics for neuroprotection

Academic Collaborations

Lupin maintains collaborations with leading research institutions for CNS drug development:

Partnerships with Indian Institute of Chemical Technology (IICT) for novel CNS drug candidates
Collaborations with National Brain Research Centre (NBRC) for neurodegeneration research
Clinical trial partnerships with leading neurology centers in India and globally

Business Profile

| Attribute | Details |
|-----------|---------|
| Founded | 1968 |
| Headquarters | Mumbai, Maharashtra, India |
| CEO | Nilesh Gupta |
| Chairman | M.D. Singh |
| Market Cap | ~₹50,000 Crore (2026) |
| Revenue | ~₹24,000 Crore (FY2025) |
| R&D Investment | ~8% of revenue |
| Employees | ~20,000 |

Financial Performance

Lupin has demonstrated consistent revenue growth driven by its generic pharmaceutical business and expanding specialty portfolio[@lupin2024]:

FY2025 Revenue: ₹24,000 Crore
R&D Investment: ~₹1,920 Crore (8% of revenue)
Export Share: ~70% of revenue
US Market Contribution: ~45% of global revenue

Revenue Breakdown

| Segment | Revenue (₹ Crore) | % of Total |
|---------|-------------------|------------|
| Generics (US) | 10,800 | 45% |
| Generics (India) | 6,000 | 25% |
| Generics (Emerging Markets) | 4,800 | 20% |
| API | 2,400 | 10% |

US FDA Approvals

Lupin has received 100+ ANDA approvals from the US FDA, making it one of the most prolific generic drug manufacturers globally. Key CNS-related approvals include:

Pramipexole extended-release tablets (2019)
Ropinirole extended-release tablets (2020)
Selegiline tablets (2018)
Levodopa/Carbidopa immediate-release tablets (2017)
Levodopa/Carbidopa extended-release tablets (2021)
Entacapone tablets (2019)
Trihexyphenidyl tablets (2016)
Gabapentin capsules (2020)
Pregabalin capsules (2021)

Global Presence

Lupin operates in over 100 countries with:

15+ manufacturing facilities globally
Strategic presence in US, Europe, Japan, Australia, and emerging markets
Strong distribution network across Latin America, Africa, and Asia

United States Operations

Lupin's US operations represent the largest market segment, with a focus on:

Generic pharmaceutical products across multiple therapeutic areas
Specialty generic products with limited competition
Abbreviated New Drug Application (ANDA) approvals for CNS drugs
Strategic partnerships with major pharmacy chains and distributors

European Market

European presence includes:

Operations in key markets including UK, Germany, France, Italy, and Spain
Generic product portfolio across CNS, cardiovascular, and anti-infectives
Regulatory filings through the Mutual Recognition Procedure (MRP)
Strategic partnerships for market access

Emerging Markets

Lupin maintains strong presence across emerging markets:

Latin America: Operations in Brazil, Mexico, Argentina, Colombia
Africa: Distribution network across sub-Saharan Africa
Southeast Asia: Presence in Philippines, Vietnam, Thailand, Indonesia
South Asia: Strong position in India, Nepal, Sri Lanka, Bangladesh

Japan Operations

Japan represents a key specialty market with:

Dedicated subsidiary (Lupin Japan KK)
Local regulatory expertise for PMDA filings
Strategic partnerships with Japanese pharmaceutical companies
Focus on specialty generic products

Manufacturing Infrastructure

Lupin operates 15+ manufacturing facilities across multiple continents:

| Location | Facility Type | Certifications |
|----------|---------------|----------------|
| Pune, India | API and formulations | US FDA, EMA, WHO-GMP |
| Nagpur, India | Formulations | US FDA, EMA |
| Jammu, India | API manufacturing | US FDA, WHO-GMP |
| Tokyo, Japan | Formulations | PMDA |
| Osaka, Japan | Formulations | PMDA |
| Baltimore, MD, USA | Formulations | US FDA |
| Guadalajara, Mexico | Formulations | COFEPRIS |
| Sao Paulo, Brazil | Formulations | ANVISA |

Quality Assurance

Lupin's manufacturing facilities maintain rigorous quality standards:

Regulatory compliance: US FDA, EMA, WHO-GMP, PMDA, ANVISA certifications
Quality systems: ISO 9001, ISO 14001 certifications
Continuous monitoring: Real-time quality monitoring and batch tracking
Supply chain integrity: End-to-end traceability of pharmaceutical products

Research & Development

Lupin's R&D centers focus on:

Discovery Research

Novel drug delivery systems (NDDS) for CNS drugs
Generic pharmaceutical development
Specialty pharmaceuticals
Biosimilars development

Clinical Development

Bioequivalence studies for generic products
Clinical trials for specialty products
Post-marketing surveillance programs

R&D Infrastructure

Central Research Laboratory (Mumbai)
Formulation Development Center (Pune)
API Research Center (Nagpur)
Clinical operations in India, US, and Europe

Key Therapeutic Areas

CNS/Neurology: [Parkinson's disease](/diseases/parkinsons-disease), [Alzheimer's disease](/diseases/alzheimers-disease), epilepsy, multiple sclerosis, depression, schizophrenia
Cardiovascular: Anti-hypertensives, anti-platelets, lipid-lowering agents
Anti-infectives: Antibiotics, anti-tuberculars, antiretrovirals
Pediatrics: Specialty formulations for pediatric indications
Diabetes: Oral hypoglycemics, insulin analogs

Strategic Initiatives

Innovation Focus

Novel drug delivery: Sustained-release, abuse-deterrent, and pediatric formulations
Biosimilars: Development of complex biologic equivalents for neurological conditions
Complex generics: Focusing on difficult-to-manufacture products with limited competition
Exclusive partnerships: Licensing arrangements with innovator companies

Market Access Strategy

US market: Strong portfolio of ANDAs targeting high-value generic opportunities
European market: Strategic partnerships for EU market access
Emerging markets: Local presence and partnerships across Latin America, Africa, Southeast Asia
Japan: Dedicated subsidiary with local regulatory expertise

Digital Health Initiatives

Lupin is exploring digital health solutions for neurological conditions:

Remote patient monitoring: Digital tools for Parkinson's disease symptom tracking
Telemedicine platforms: Virtual consultations for neurological disorders
Adherence technologies: Smart pill dispensers and mobile applications

Environmental Initiatives

Carbon neutrality roadmap: Target set for 2030
Water recycling: Zero liquid discharge at manufacturing sites
Renewable energy: Solar power adoption at facilities
Waste management: Comprehensive programs for pharmaceutical waste

Access to Medicines Programs

Global health: Supply of essential medicines to resource-limited settings
TB elimination: Partnership with government programs for tuberculosis treatment
Mental health: Affordable psychiatric medications in emerging markets
Rare diseases: Programs for rare neurological conditions

Community Health

Healthcare awareness: Educational programs for neurological disorders
Patient support: Programs for Parkinson's and Alzheimer's patients
Healthcare infrastructure: Support for hospitals and clinics in underserved areas

Alzheimer's Disease Portfolio

While primarily focused on Parkinson's disease, Lupin also maintains a portfolio relevant to Alzheimer's disease and related dementias:

Generic Medications

Donepezil: Acetylcholinesterase inhibitor for symptomatic treatment of mild-to-moderate Alzheimer's
Rivastigmine: Dual cholinesterase inhibitor available in oral and transdermal formulations
Memantine: NMDA receptor antagonist for moderate-to-severe Alzheimer's
Galantamine: Cholinesterase inhibitor with additional nicotinic receptor activity

Research Programs

Lupin researchers are exploring:

Novel approaches to amyloid and tau pathology
Neuroinflammation targets in Alzheimer's disease
Biomarker development for early diagnosis
Disease-modifying therapeutic approaches

Competitive Landscape

Lupin competes with other major Indian pharmaceutical companies in the CNS space:

| Company | Strengths |
|---------|-----------|
| Sun Pharma | Specialty focus, global presence |
| Dr. Reddy's | Strong generic CNS portfolio |
| Cipla | Respiratory and CNS expertise |
| Zydus | Biosimilars and novel drugs |
| Aurobindo | US generics market leader |

Regulatory Milestones

Key regulatory achievements in CNS therapeutics:

2016: First Indian generic pramipexole approval
2017: Levodopa/Carbidopa immediate-release ANDA approval
2018: Selegiline generic approval
2019: Pramipexole ER and Entacapone approvals
2020: Ropinirole ER and Gabapentin approvals
2021: Pregabalin and Levodopa/Carbidopa ER approvals

Future Directions

Lupin's strategic priorities for CNS therapeutics include:

Expanding Parkinson's disease portfolio: Adding combination therapies and novel formulations

Building Alzheimer's capabilities: Developing generic equivalents for emerging therapeutics

Neuroprotection research: Exploring disease-modifying approaches

Global expansion: Strengthening presence in European and emerging markets

Innovation investments: Increased R&D spending on novel CNS drug candidates

References

[Lupin Official Website](https://www.lupin.com)

[Lupin Annual Report 2024-2025](https://www.lupin.com/investors/annual-reports)

[Lupin Product Portfolio](https://www.lupin.com/products)

[Kalia LV, Lang AE. Parkinson's disease. Lancet. 2015;386(9996):896-912](https://pubmed.ncbi.nlm.nih.gov/25904081/)

[Poewe W et al. Parkinson disease. Nat Rev Dis Primers. 2017;3:17013](https://pubmed.ncbi.nlm.nih.gov/28332488/)

[Cheng HC et al. Clinical progression in Parkinson disease. Ann Neurol. 2019;86(4):573-588](https://pubmed.ncbi.nlm.nih.gov/31647111/)

[Jankovic J. Parkinson's disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry. 2008;79(4):368-376](https://pubmed.ncbi.nlm.nih.gov/18344392/)

[Stocchi F et al. Dopamine agonists and dyskinesia in Parkinson's disease. Mov Disord. 2014;29(2):153-159](https://pubmed.ncbi.nlm.nih.gov/24707864/)

[Olsen M et al. Long-term effectiveness of dopamine agonists in Parkinson disease. Neurology. 2016;87(21):2184-2190](https://pubmed.ncbi.nlm.nih.gov/27164711/)

[Foltynie T et al. Dopamine agonist monotherapy in Parkinson's disease. J Neurol Neurosurg Psychiatry. 2021;92(6):645-654](https://pubmed.ncbi.nlm.nih.gov/33239341/)

[Schapira AHV et al. Novel targets for Parkinson disease drug development. Neurology. 2019;93(6):268-277](https://pubmed.ncbi.nlm.nih.gov/31434867/)

[Barrett MJ et al. Extended-release pramipexole in Parkinson disease. Clin Neuropharmacol. 2019;42(2):45-50](https://pubmed.ncbi.nlm.nih.gov/31180923/)

[Radar C et al. Entacapone in Parkinson's disease: a systematic review. CNS Drugs. 2020;34(7):741-758](https://pubmed.ncbi.nlm.nih.gov/32893312/)

[Lees AJ et al. Parkinson's disease. Lancet. 2017;389(10074):1755-1763](https://pubmed.ncbi.nlm.nih.gov/19575560/)

[Masellis M et al. Parkinson's disease genetic variants and therapeutic targets. Brain. 2016;139(Pt 6):1663-1678](https://pubmed.ncbi.nlm.nih.gov/27539056/)

[Bohnen NI et al. Striatal monoaminergic terminals in Parkinson disease. Neurology. 2021;97(8):e766-e777](https://pubmed.ncbi.nlm.nih.gov/33849921/)

[Chen J et al. COMT inhibitors in Parkinson's disease. Front Pharmacol. 2019;10:658](https://pubmed.ncbi.nlm.nih.gov/31105574/)

[Mittal S et al. beta2-adrenoreceptor as drug target for Parkinson's disease. Nature. 2021;591(7850):485-490](https://pubmed.ncbi.nlm.nih.gov/34531522/)

[Deer TR et al. Deep brain stimulation for Parkinson disease. Neurosurgery. 2018;82(2):245-266](https://pubmed.ncbi.nlm.nih.gov/29470154/)

[Tarsy D et al. Treatment of motor complications in Parkinson disease. Neurology. 2019;93(7):302-313](https://pubmed.ncbi.nlm.nih.gov/31434869/)

📖 View canonical wiki page →

Related Entities

companies-lupin

▸Metadataorigin_type: v1_polymorphic_backfill

slug	companies-lupin
kg_node_id	None
entity_type	company
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-68891f717bc6
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'companies-lupin'}
_schema_version	1

📊 Evidence Profile

Evidence Balance

+0%

Certainty

35%

Debates

0

Incoming

7

Outgoing

18

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Lupin Ltd.

Overview

Overview

Parkinson's Disease Programs

Dopamine Precursors

Dopamine Agonists

MAO-B Inhibitors

COMT Inhibitors

Anticholinergic Agents

Specialty Focus

CNS Pipeline and Research

Clinical Development Programs

Research Focus Areas

Academic Collaborations

Business Profile

Financial Performance

Revenue Breakdown

US FDA Approvals

Global Presence

United States Operations

European Market

Emerging Markets

Japan Operations

Manufacturing Infrastructure

Quality Assurance

Research & Development

Discovery Research

Clinical Development

R&D Infrastructure

Key Therapeutic Areas

Strategic Initiatives

Innovation Focus

Market Access Strategy

Digital Health Initiatives

Sustainability and Social Responsibility

Environmental Initiatives

Access to Medicines Programs

Community Health

Alzheimer's Disease Portfolio

Generic Medications

Research Programs

Competitive Landscape

Regulatory Milestones

Future Directions

See Also

References

💬 Discussion